What changed in Grifols SA's 2024 10-K compared to 2023?

Across the narrative sections we track, Grifols SA (GRFS) added 0 paragraphs, removed 0, and edited 0 between the 2023 and 2024 10-K filings. The biggest movers are .

Where does this GRFS 10-K diff come from?

The source filings are Grifols SA's official 2023 and 2024 Form 20-F annual reports from SEC EDGAR. 10q10k.net parses each filing, aligns paragraphs by section (Item 1, 1A, 1C, 2, 3, 7, 7A), and highlights every added, removed and edited sentence side-by-side.

Grifols SAGRFS決算レポート

Nasdaq · pharmaceutical industry

Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.

What changed in Grifols SA's 20-F — 2023 vs 2024

No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.

Other GRFS 10-K year-over-year comparisons

GRFS 10-K 2022 vs 2023